Joint Enhancer
Introduce
Joint Enhancer is a functional supplements supporting bone and joint health. UC-II®, as one of important active ingredients in bone and joint product, is a patented form of undenatured (native) type II collagen that works with the body's immune system to improve joint mobility and flexibility, maintain healthy joints. UC-II® is the principal structural protein composed cartilage and used to replenish the lost collagen in bone and joints for the seniors and menopausal women.*
Human clinical research demonstrates that just 40 mg daily of UC-II® supports joint comfort, flexibility and mobility. The latest randomized, double-blind study shows that UC-II® provided significantly better results than glucosamine + chondroitin in increasing joint function.*
UC-II® is a FDA-notified and published new dietary ingredient (NDI). UC-II® is the only source of undenatured type II collagen available as a powdered, shelf stable dietary ingredient.
It's the only collagen product approved for research by Dr. David Trentham, the Harvard rheumatology professor who led clinical studies on the effectiveness of type II collagen.
UC-II® is manufactured in a US GMP-certified facility from chicken sternum cartilage using a patented, low-temperature manufacturing process that ensures a particular level of undenatured type II collagen. UC-II® was determined GRAS in an intensive review of all safety and toxicology data by a panel of renowned United States scientific experts.
- *This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions.
Research
Here, you can read some of important published clinical research papers about UC-II, which support its efficacy on improving joint mobility and flexibility. Published peer reviewed studies can be accessed through PubMed at www.ncbi.nlm.nih.gov/pubmed. For more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
UC-II Proven to be more effective than glucosamine & chondroitin for osteoarthritis
Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study
Abstract
Background: Undenatured type II collagen (UC-II) is a nutritional supplement derived from chicken sternum cartilage. The purpose of this study was to evaluate the efficacy and tolerability of UC-II for knee osteoarthritis (OA) pain and associated symptoms compared to placebo and to glucosamine hydrochloride plus chondroitin sulfate (GC).
Methods: One hundred ninety one volunteers were randomized into three groups receiving a daily dose of UC-II (40 mg), GC (1500 mg G & 1200 mg C), or placebo for a 180-day period. The primary endpoint was the change in total Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) from baseline through day 180 for the UC-II group versus placebo and GC. Secondary endpoints included the Lequesne Functional Index (LFI), the Visual Analog Scale (VAS) for pain and the WOMAC subscales. Modified intent-to-treat analysis were performed for all endpoints using analysis of covariance and mixed model repeated measures, while incremental area under the curve was calculated by the intent-to-treat method.
Results: At day 180, the UC-II group demonstrated a significant reduction in overall WOMAC score compared to placebo (p = 0.002) and GC (p = 0.04). Supplementation with UC-II also resulted in significant changes for all three WOMAC subscales: pain (p = 0.0003 vs. placebo; p = 0.016 vs. GC); stiffness (p = 0.004 vs. placebo; p=0.044 vs. GC); physical function (p = 0.007 vs. placebo). Safety outcomes did not differ among the groups.
Conclusion: UC-II improved knee joint symptoms in knee OA subjects and was well-tolerated. Additional studies that elucidate the mechanism for this supplement’s actions are warranted.
Source: Lugo et al. Nutrition Journal (2016) 15:14
Toxicological evaluation showed a broad-spectrum safety profile of UC-II
Safety and toxicological evaluation of undenatured type II collagen.
Abstract: Previous research has shown that undenatured type II collagen is effective in the treatment of arthritis. The present study evaluated the broad-spectrum safety of UC-II by a variety of toxicological assays including acute oral, acute dermal, primary dermal irritation, and primary eye irritation toxicity. In addition, genotoxicity studies such as Ames bacterial reverse mutation assay and mouse lymphoma tests, as well as a dose-dependent 90-day sub-chronic toxicity study were conducted. Safety studies indicated that acute oral LD(50) of UC-II was greater than 5000 mg/kg in female Sprague-Dawley rats. No changes in body weight or adverse effects were observed following necropsy. Acute dermal LD(50) of UC-II was determined to be greater than 2000 mg/kg. Primary skin irritation tests conducted on New Zealand Albino rabbits classified UC-II as slightly irritating. Primary eye irritation tests conducted on rabbits indicated that UC-II was moderately irritating to the eye. UC-II did not induce mutagenicity in the bacterial reverse mutation test in five Salmonella typhimurium strains either with or without metabolic activation. Similarly, UC-II did not induce a mutagenic effect in the gene mutation test in mouse lymphoma cells either with or without metabolic activation. A dose-dependent 90-day sub-chronic toxicity study revealed no pathologically significant changes in selected organ weights individually or as percentages of body or brain weights. No significant changes were observed in hematology and clinical chemistry. Therefore, the results from the current study show a broad-spectrum safety profile of UC-II.
Source: Toxicol Mech Methods. 2010 May;20(4):175-189.
Safety and efficacy of UC-II in the treatment of osteoarthritis of the knee
Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial
Abstract: Previous studies have shown that undenatured type II collagen (UC-II) is effective in the treatment of rheumatoid arthritis, and preliminary human and animal trials have shown it to be effective in treating osteoarthritis (OA). The present clinical trial evaluated the safety and efficacy of UC-II as compared to a combination of glucosamine and chondroitin (G+C) in the treatment of OA of the knee. The results indicate that UC-II treatment was more efficacious resulting in a significant reduction in all assessments from the baseline at 90 days; whereas, this effect was not observed in G+C treatment group. Specifically, although both treatments reduced the Western Ontario McMaster Osteoarthritis Index (WOMAC) score, treatment with UC-II reduced the WOMAC score by 33% as compared to 14% in G+C treated group after 90 days. Similar results were obtained for visual analog scale (VAS) scores. Although both the treatments reduced the VAS score, UC-II treatment decreased VAS score by 40% after 90 days as compared to 15.4% in G+C treated group. The Lequesne’s functional index was used to determine the effect of different treatments on pain during daily activities. Treatment with UC-II reduced Lequesne’s functional index score by 20% as compared to 6% in G+C treated group at the end of 90-day treatment. Thus, UC-II treated subjects showed significant enhancement in daily activities suggesting an improvement in their quality of life.
Source: Int.J.Med.Sci.2009; 6(6):312-321
Research data from Harvard shown efficacy of type II collagen in Rheumatoid Arthritis
Effects of oral administration of type II collagen on rheumatoid arthritis.
Abstract: Rheumatoid arthritis is an inflammatory synovial disease thought to involve T cells reacting to an antigen within the joint. Type II collagen is the major protein in articular cartilage and is a potential autoantigen in this disease. Oral tolerization to autoantigens suppresses animal models of T cell-mediated autoimmune disease, including two models of rheumatoid arthritis. In this randomized, double-blind trial involving 60 patients with severe, active rheumatoid arthritis, a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Four patients in the collagen group had complete remission of the disease. No side effects were evident. These data demonstrate clinical efficacy of an oral tolerization approach for rheumatoid arthritis.
Source: Science 24 September 1993:Vol. 261 no. 5129 pp. 1727-1730
Comparative efficacy of UC-II, glucosamine and chondroitin in arthritic animals
Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to
glucosamine and chondroitin in arthritic horses.
Abstract: The present investigation evaluated arthritic pain in horses receiving daily placebo, undenatured type II collagen (UC-II) at 320, 480, or 640 mg (providing 80, 120, and 160 mg active UC-II, respectively), and glucosamine and chondroitin (5.4 and 1.8 g, respectively, bid for the first month, and thereafter once daily) for 150 days. Horses were evaluated for overall pain, pain upon limb manipulation, physical examination, and liver and kidney functions. Evaluation of overall pain was based upon a consistent observation of all subjects during a walk and a trot in the same pattern on the same surface. Pain upon limb manipulation was conducted after the walk and trot. It consisted of placing the affected joint in severe flexion for a period of 60 sec. The limb was then placed to the ground and the animal trotted off. The response to the flexion test was then noted with the first couple of strides the animal took. Flexion test was consistent with determining clinically the degree of osteoarthritis in a joint. Horses receiving placebo showed no change in arthritic condition, while those receiving 320 or 480 or 640 mg UC-II exhibited significant reduction in arthritic pain (P < 0.05). UC-II at 480 or 640 mg dose provided equal effects, and therefore, 480 mg dose was considered optimal. With this dose, reduction in overall pain was from 5.7 ± 0.42 (100%) to 0.7 ± 0.42 (12%); and in pain upon limb manipulation from 2.35 ± 0.37 (100%) to 0.52 ± 0.18 (22%). Although glucosamine and chondroitin treated group showed significant (P < 0.05) reduction in pain compared with pretreated values, the efficacy was less compared with that observed with UC-II. In fact, UC-II at 480 or 640 mg dose was found to be more effective than glucosamine and chondroitin in arthritic horses. Clinical condition (body weight, body temperature, respiration rate, and pulse rate), and liver (bilirubin, GGT, and ALP) and kidney (BUN and creatinine) functions remained unchanged, suggesting that these supplements were well tolerated.
Source: J Vet Pharmacol Ther. 2009 Dec;32(6):577-84
FAQs
UC-II® is a patented form of undenatured (native) type II collagen that derived from chicken sternum cartilage at low temperature. UC-II works with the body's immune system to improve joint mobility and flexibility, maintain healthy joints.* The latest randomized, double-blind, placebo-controlled clinical study shows that UC-II® provided significant results compared to placebo in increasing joint function.*
UC-II® is manufactured in a GMP-certified facility from chicken sternum cartilage using a patented, low-temperature manufacturing process that ensures a particular level of undenatured type II collagen. Based on laboratory and clinical studies, the makers claim that the undenatured collagen in UC-II differs from hydrolyzed or denatured collagen because it contains active immune modulators that reduce the secretion of enzymes that break down type II collagen, thereby slowing the inflammatory response.
A 2016 study published in Nutrition Journal divided 191 people with osteoarthritis into three groups: one group received placebo; one group received UC-II and the third group received glucosamine hcl and chondroitin sulfate supplements. After 180 days of treatment, the UC-II group had better pain, stiffness, and function than the placebo group and the G+C group.
UC-II studies done on people with rheumatoid arthritis have had exciting results. A 2009 double-blind trial that included more than 500 people with RA found that undenatured collagen improved participants’ pain, morning stiffness, tender joint count and swollen joint count. The study, published in Arthritis Research and Therapy, concluded that UC-II is safe and effective in the treatment of RA.
Undenatured type II collagen administered orally works with a healthy immune system to promote healthy joints by a process called oral tolerization. This process helps the body to differentiate between foreign invaders, such as bacteria, and elements that are good for the body, such as nutrients. The process of oral tolerization takes place in the small intestine where food is absorbed. Through a complex process, lymphoid tissue in the mucosal lining of the small intestine screens incoming compounds and serves as a "switch" turning the body's immune response on or off to foreign substances, depending upon what that substance is. In the case of undenatured type II chicken collagen, small amounts (typically around 10 milligrams) taken orally have been shown to correct a faulty immune response specifically targeted at the type II collagen present in bone joint cartilage -- in effect, modulating the body's immune response so it works correctly once again.*
There have been a number of studies conducted with UC-II on both animals and humans, including research at the Harvard University Medical school -- all of which have shown that the undenatured type II chicken collagen found in UC-II effectively reprograms the immune system to promote healthy joints and increase joint mobility and flexibility.*
UC-II was also found to be safe in liver, kidney and heart functions of dogs as demonstrated by serum ALT, BUN and CK levels. The present study examined the acute oral toxicity, acute dermal toxicity, primary dermal and primary eye irritation, and Ames' bacterial reverse mutation assay. Results indicate that LD50 of UC-II is greater than 5,000 mg/kg when administered orally in male and female Sprague Dawley rats. Acute dermal toxicity of UC-II is greater than 2,000 mg/kg in both male and female rats. Primary dermal irritation in male and female New Zealand albino rabbits is slightly irritating. The overall irritation decreased within 24 hr. Primary eye irritation in albino rabbits was slightly and all animals were free of ocular irritation within 48 hrs. UC-II did not induce mutagenic effects in the Ames' bacterial reverse mutation test in five Salmonella typhimurium strains. Taken together, these results demonstrate the broad spectrum safety in animal and human.*
- *This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions.
Where to Buy
For Consignee in Mainland China
The customers in China, please visit local agent's website to purchase: www.bhsd.cn, or click below button for your order. International shipping charge waived for any order over 6 bottles.
For Consignee in the United States
If your consignees locate in the United States, please click this section to make your orders. The consignees in Mainland, China, please use left one.